Stocks
Axsome Therapeutics (AXSM) EBITDA margin US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2023 | 2024 | 2025 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | -350.5% | -83.1% | -70.7% | -26.3% | -24.4% | |||
| Changes by years, y/y, % | +267pp | +12pp | +44pp | -57.8% | |||||
Axsome Therapeutics. EBITDA margin, %
Axsome Therapeutics. EBITDA margin, changes, pp
Axsome Therapeutics (AXSM) EBITDA margin US GAAP (quarter values) |
||||||||
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | LTM ? | |||
| EBITDA margin, % | ? | -45.2% | -28.4% | -26.0% | -12.6% | -31.9% | -24.4% | |
| Changes by years, y/y, % | +42pp | +59pp | +32pp | +47pp | +13pp | |||
| Changes by quarters, q/q, % | +14pp | +17pp | +2pp | +13pp | -19pp | |||
